FDA Grant Symbicort Six Months Exclusivity
News Jan 30, 2017
AstraZeneca announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of paediatric exclusivity for Symbicort (budesonide/formoterol) Inhalation Aerosol.
The FDA’s decision was based on the evaluation of trials conducted in children with asthma aged six up to 12 years in response to a Written Request (a prerequisite for qualifying for paediatric exclusivity under Section 505A of the Federal Food, Drug, and Cosmetic Act). Symbicort is currently approved in the US to treat asthma in patients 12 years and older and for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) in adults.
This article has been republished from materials provided by Astra Zeneca. Note: material may have been edited for length and content. For further information, please contact the cited source.
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Bacteria Produce More Substances Than Genetics PredictedNews
Tandem mass spectrometry has revealed that Streptomyces chartreusis, an antibiotic-producing bacterium, releases more metabolites into the surrounding medium than scientists assumed based on the analysis of the genome. They might include molecules that are of interest as potential pharmaceutical agents.READ MORE